The aim of this study was to investigate the influence of a chromosome abnormality on male infertility. The subjects consisted of 1,007 males with the chief complaint of infertility. Karyotyping was conducted mainly by G banding. Major chromosome abnormalities were observed in 62 patients (6.2%) in total and consisted of sex chromosome abnormalities in 38 patients (3.8%) and autosomal chromosome abnormalities in 24 (2.4%). Among the patients with sex chromosome abnormalities, 28 cases were 47, XXY, 3 were 47, XYY, and 7 cases had a Y chromosome abnormality. Autosomal chromosome abnormalities comprised 10 cases of reciprocal translocation, 8 cases of Robertsonian translocation, 5 cases of inversion, and 1 case of ring chromosome. In patients with a sperm density < 5 × 106/ml, a total motile sperm count < 1 × 106, a follicle-stimulating hormone value = 30.1 mlU/ml, a luteinizing hormone value = 8.9 mlU/ml, a testosterone value ≤ 2.69 ng/ml, or an average testis volume ≤ 8 ml, the incidence of major chromosome abnormalities was significantly higher. These findings suggest that patients who need microinsemination should undergo chromosome analysis. We should counsel patients about obtaining adequate information on each chromosome abnormality.

Keywords:
Chromosome abnormality, Cytogenetic survey, Male infertility, Testis
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.